MENLO PARK, CA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)GRACE SCIENCE FOUNDATION, founded in 2014, is a small nonprofit in the Medical Research sector that reported $943K in total revenue in fiscal year 2024. Revenue grew 14% year-over-year, indicating healthy expansion. Expenses of $1.5M exceeded revenue, resulting in a 61% operating deficit.
THE MISSION OF THE FOUNDATION IS TO SUPPORT AND FUND THE DEVELOPMENT OF LIFE-SAVING TREATMENT FOR PATIENTS THAT ARE DEFICIENT IN THE N-GLYCANESE ENZYME AND THOSE SUFFERING FROM RELATED GENETIC DISEASES. THE ACTIVITIES OF THE FOUNDATION WILL INVOLVE PROVIDING GRANT FUNDING TO HOSPITALS AND MEDICAL RESESARCH FACILITIES WHICH ARE CONDUCTING MEDICAL RESEARCH IN VARIOUS FIELDS RELATING TO THE SEARCH FOR UNDERSTNADING AND TREATMENT OF THIS CONDITION, FOSTERING COLLABORATION BETWEEN ACADEMIA, RESEARCH INSTITUTIONS, HOSPITALS, PRIVATE COMPANIES, AND GOVERNMENTAL AGENCIES.
Baylor College of Medicine NGLY1 Natural History Study (Bernhard Suter) Team is conducting a natural history study to define the clinical spectrum of the disease and its progression, and define...
Baylor College of Medicine NGLY1 Natural History Study (Bernhard Suter) Team is conducting a natural history study to define the clinical spectrum of the disease and its progression, and define biomarker endpoints for use in therapeutic trials. This study is led by Dr. Bernhard Suter, MD, a child neurologist and medical geneticist. The study is collecting longitudinal measures of movement concurrently with clinical and biomarker measures to define aspects of gait and movement that are most affected in the disorder, characterize progression of the disease, select clinical features for performing longitudinal assessments, and inform clinical endpoint development for therapeutic trials.
Psychogenics Inc. Team has imported and is analyzing mouse and rat models of NGLY1 Deficiency for testing of candidate therapies. Team has conducted several studies using an NGLY1 knockout rat model...
Psychogenics Inc. Team has imported and is analyzing mouse and rat models of NGLY1 Deficiency for testing of candidate therapies. Team has conducted several studies using an NGLY1 knockout rat model to test phenotypic rescue using candidate small molecule therapies (both novel and approved drugs).
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (YAN LAB) Team continues work generating and characterizing several mouse models of NGLY1 Deficiency, including models in which the gene is...
THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (YAN LAB) Team continues work generating and characterizing several mouse models of NGLY1 Deficiency, including models in which the gene is inactivated in certain tissues and conditionally after birth. These mouse models have allowed them to characterize neurological phenotypes including neuronal loss, neuropathological changes, inflammation, sensory and motor defects, and disease associated biomarkers, all of which are also observed in NGLY1 Deficiency patients These animal models provide a foundation for testing candidate therapies, including gene therapies and small molecule drugs. The team has also found that NGLY1 Deficiency in mice triggers a specific innate immune pathway mediated by the cGAS/STING pathway. Using genetic and pharmacological approaches, the team has uncovered three different targets that can be modulated to reduce disease associated phenotypes and improve survival.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $943,011 | $826,626 | +0.1% |
| Expenses | $1,519,386 | $1,289,174 | +0.2% |
| Net Income | $-576,375 | $-462,548 | +0.2% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| Matthew Wilsey | President | 0.0 |
Officer
Director
|
$0 | $0 | $0 |
| Egon Durban | Chief Financial Officer | 0.0 |
Officer
Director
|
$0 | $0 | $0 |
| KEN DRAZAN | Secretary | 0.0 |
Officer
Director
|
$0 | $0 | $0 |
| Pete Briger | Director | 0.0 |
Director
|
$0 | $0 | $0 |
| Chelsea Clinton | Director | 0.0 |
Director
|
$0 | $0 | $0 |
| J Taylor Crandall | Director | 0.0 |
Director
|
$0 | $0 | $0 |
| Elle Stephens | Director | 0.0 |
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $943,011 | $1,519,386 | $2,224,370 | $-576,375 |
| 2023 | $826,626 | $1,289,174 | $2,790,274 | $-462,548 |
| 2022 | $1,236,228 | $1,218,482 | $3,183,591 | $17,746 |
| 2021 | $1,327,113 | $1,113,132 | $3,128,030 | $213,981 |
| 2020 | $1,454,180 | $1,452,901 | $2,884,506 | $1,279 |
| 2019 | $1,561,302 | $839,395 | $2,889,615 | $721,907 |
| 2018 | $1,199,988 | $1,074,064 | $2,196,374 | $125,924 |
Compare GRACE SCIENCE FOUNDATION with other nonprofits in California and across the country.